Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there An…
